CMS Open Payments · Program Year 2024
American Rheumatology Network, LLC
American Rheumatology Network, LLC reported $15,919,952.40 across General Payments, Research, and Ownership to 12 physicians and teaching hospitals across 18 transactions.
- $15.9M Top 10% payer
- All-tracks total
- 18 Below-median volume
- Transactions
- 12 Below-median reach
- Recipients
- −$9.0K
- General Payments vs PY2023
American Rheumatology Network, LLC reported $15,919,952.40 across all CMS Open Payments tracks (General + Research + Ownership) to 12 physicians and teaching hospitals in Program Year 2024 - ranking #119 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $2,801,556.80, averaging $1.3M per recipient.
How American Rheumatology Network, LLC's $15.9M all-tracks total breaks down
American Rheumatology Network, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
36/100
Total payments
A
100/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer american-rheumatology-network-llc American Rheumatology Network, LLC
$15.9M · #119/1,925 · 0.1% industry · PY2024
- TOT $15.9M
- RANK #119
- SHARE 0.1%
- TXN 18
- RCP 12
- CAT 2
- GEN $2.8M
- ΔGEN −$9.0K
- TOP1 53.5%
- PY 2024
Volume peers
Nearest volume peer: Heartflow, Inc. ($16.0M)
American Rheumatology Network, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
American Rheumatology Network, LLC's CMS-reported General Payments decreased by $9.0K (−0.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AMERICAN RHEUMATOLOGY NETWORK, LLCPY2023: AMERICAN RHEUMATOLOGY NETWORK, LLCPY2024: American Rheumatology Network, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,810,550.47
- PY2024
- $2,801,556.80
What the Data Shows for American Rheumatology Network, LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For American Rheumatology Network, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
1 transactions worth $1.5M make "Acquisitions" the top general-payment category in the 2-category breakdown below, 53.5% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
American Rheumatology Network, LLC made 2 types of general payments. "Acquisitions" is the largest category at $1.5M, 53.5% of General Payments.
How American Rheumatology Network, LLC divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Acquisitions | $1.5M | 1 | 53.5% |
| Consulting Fee | $1.3M | 11 | 46.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,685,485.37 (95.9%) of $2,801,556.80 in this company's General Payments records across 6 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for American Rheumatology Network, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Colin Edgerton
$1,500,000.00 across 1 reported transactions
- 2
Clarence Legerton
$432,646.53 across 3 reported transactions
- 3
Gary Fink
$432,646.53 across 3 reported transactions
- 4
William Edwards
$204,120.88 across 3 reported transactions
- 5
Gregory Niemer
$116,071.43 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
American Rheumatology Network, LLC ranks #119 of 1,925 by total payments (top 6% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #515 of 1,838 by HHI (top 28% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Novabone Products : $19.0K total payments, HHI 3461
- NovoSource, LLC : $22.9K total payments, HHI 3460
- Datascope Corp. : $1.6M total payments, HHI 3460
- Bristol Myers Squibb Company : $1.0M total payments, HHI 3447
- Collegium Pharmaceutical, Inc. : $1.5M total payments, HHI 3442
- Granata Bio Corporation : $5.5K total payments, HHI 3437
- American Rheumatology Network, LLC (this company) : $2.8M total payments, HHI 3431
- Biocircuit Technologies Inc : $69.8K total payments, HHI 3424
- Organ Recovery Systems, Inc. : $356.7K total payments, HHI 3422
- Omniscient Neurotechnology America Ltd : $73.2K total payments, HHI 3397
- FlexDex Inc. : $350.51 total payments, HHI 3376
- Seres Therapeutics, Inc. : $132.4K total payments, HHI 3375
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as American Rheumatology Network, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about American Rheumatology Network, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with American Rheumatology Network, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Organon Llc
Bausch & Lomb Americas Inc.
Philips North America LLC
SPR Therapeutics, Inc
Aveo Pharmaceuticals, Inc.
Put this to use
American Rheumatology Network, LLC ranks #119 of 1,925 by all-tracks total payments, led by "Acquisitions".
- See where American Rheumatology Network, LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Acquisitions" spend across every manufacturer, not just American Rheumatology Network, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.